The inherited retinal disease (IRD) community has received encouraging news regarding the development of potential new treatments. Ocugen, Inc., a biopharmaceutical company, announced on February 23, 2021, that the European Commission granted Orphan Medicinal Product Designation to its gene therapy product candidate, OCU400, for the treatment of both Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA).

What This Means for the IRD Community

This designation is a significant step in the development process for OCU400. Orphan Medicinal Product Designation is granted to medicines intended for the diagnosis, prevention, or treatment of life-threatening or very serious conditions that affect no more than 5 in 10,000 people in the European Union. Both RP and LCA are considered rare, chronically debilitating groups of IRDs that can lead to severe vision impairment and often total blindness.

According to Ocugen, the prevalence of RP in Europe is estimated at approximately 165,000 patients, and LCA affects an estimated 40,000 patients in Europe. Dr. Mohamed Genead, acting chief medical officer of Ocugen, highlighted the unmet need for new treatment options, noting that existing approved therapies address only a small percentage of this patient population.

Key Facts About OCU400

OCU400 is an investigational gene therapy based on Ocugen's modifier gene therapy platform. It is designed to deliver a functional copy of the nuclear hormone receptor gene NR2E3 to target cells in the retina using an adeno-associated viral (AAV) vector. Nuclear hormone receptors, such as NR2E3, are important for retinal development and function. The therapy aims to help restart retinal homeostasis, stabilize cells, and potentially rescue photoreceptors from degeneration.

This approach is particularly noteworthy because IRDs associated with RP and LCA can be caused by mutations in over 175 different genes, making gene-specific therapies challenging to develop for every mutation. Ocugen believes OCU400 has the potential to address a significant number of patients globally in a